Compounds > 2-(4-(2-carboxyethyl)phenethylamino)-5--n-ethylcarboxamidoadenosine

2-(4-(2-carboxyethyl)phenethylamino)-5--n-ethylcarboxamidoadenosine and Venous-Thrombosis

2-(4-(2-carboxyethyl)phenethylamino)-5--n-ethylcarboxamidoadenosine has been researched along with Venous-Thrombosis* in 1 studies

Other Studies

1 other study(ies) available for 2-(4-(2-carboxyethyl)phenethylamino)-5--n-ethylcarboxamidoadenosine and Venous-Thrombosis

ArticleYear
Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome.
    Nature communications, 2019, 04-23, Volume: 10, Issue:1

    Potentiation of neutrophil extracellular trap (NET) release is one mechanism by which antiphospholipid antibodies (aPL Abs) effect thrombotic events in patients with antiphospholipid syndrome (APS). Surface adenosine receptors trigger cyclic AMP (cAMP) formation in neutrophils, and this mechanism has been proposed to regulate NETosis in some contexts. Here we report that selective agonism of the adenosine A

    Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Cyclic AMP; Dipyridamole; Disease Models, Animal; Extracellular Traps; Fibrinolytic Agents; Gene Expression Regulation; Humans; Immunoglobulin G; Male; Mice; Mice, Inbred C57BL; Neutrophils; Phenethylamines; Receptor, Adenosine A2A; Signal Transduction; Vena Cava, Inferior; Venous Thrombosis

2019